Update on Paraneoplastic Cerebellar Degeneration

<b>Purpose of review:</b> To provide an update on paraneoplastic cerebellar degeneration (PCD), the involved antibodies and tumors, as well as management strategies. <b>Recent findings:</b> PCD represents the second most common presentation of the recently established class o...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Philipp Alexander Loehrer, Lara Zieger, Ole J. Simon
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	paraneoplastic cerebellar degeneration immune-mediated cerebellar ataxias paraneoplastic syndromes onconeuronal antibodies Yo-antibody Tr/DNER-antibody Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571
Acceso en línea:	https://doaj.org/article/da0a4808024c47eebf6ab585dbdd5942
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:da0a4808024c47eebf6ab585dbdd5942
record_format	dspace
spelling	oai:doaj.org-article:da0a4808024c47eebf6ab585dbdd59422021-11-25T16:56:45ZUpdate on Paraneoplastic Cerebellar Degeneration10.3390/brainsci111114142076-3425https://doaj.org/article/da0a4808024c47eebf6ab585dbdd59422021-10-01T00:00:00Zhttps://www.mdpi.com/2076-3425/11/11/1414https://doaj.org/toc/2076-3425<b>Purpose of review:</b> To provide an update on paraneoplastic cerebellar degeneration (PCD), the involved antibodies and tumors, as well as management strategies. <b>Recent findings:</b> PCD represents the second most common presentation of the recently established class of immune mediated cerebellar ataxias (IMCAs). Although rare in general, PCD is one of the most frequent paraneoplastic presentations and characterized clinically by a rapidly progressive cerebellar syndrome. In recent years, several antibodies have been described in association with the clinical syndrome related to PCD; their clinical significance, however, has yet to be determined. The 2021 updated diagnostic criteria for paraneoplastic neurologic symptoms help to establish the diagnosis of PCD, direct cancer screening, and to evaluate the presence of these newly identified antibodies. Recognition of the clinical syndrome and prompt identification of a specific antibody are essential for early detection of an underlying malignancy and initiation of an appropriate treatment, which represents the best opportunity to modulate the course of the disease. As clinical symptoms can precede tumor diagnosis by years, co-occurrence of specific symptoms and antibodies should prompt continuous surveillance of the patient. <b>Summary:</b> We provide an in-depth overview on PCD, summarize recent findings related to PCD, and highlight the transformed diagnostic approach.Philipp Alexander LoehrerLara ZiegerOle J. SimonMDPI AGarticleparaneoplastic cerebellar degenerationimmune-mediated cerebellar ataxiasparaneoplastic syndromesonconeuronal antibodiesYo-antibodyTr/DNER-antibodyNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571ENBrain Sciences, Vol 11, Iss 1414, p 1414 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	paraneoplastic cerebellar degeneration immune-mediated cerebellar ataxias paraneoplastic syndromes onconeuronal antibodies Yo-antibody Tr/DNER-antibody Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571
spellingShingle	paraneoplastic cerebellar degeneration immune-mediated cerebellar ataxias paraneoplastic syndromes onconeuronal antibodies Yo-antibody Tr/DNER-antibody Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Philipp Alexander Loehrer Lara Zieger Ole J. Simon Update on Paraneoplastic Cerebellar Degeneration
description	<b>Purpose of review:</b> To provide an update on paraneoplastic cerebellar degeneration (PCD), the involved antibodies and tumors, as well as management strategies. <b>Recent findings:</b> PCD represents the second most common presentation of the recently established class of immune mediated cerebellar ataxias (IMCAs). Although rare in general, PCD is one of the most frequent paraneoplastic presentations and characterized clinically by a rapidly progressive cerebellar syndrome. In recent years, several antibodies have been described in association with the clinical syndrome related to PCD; their clinical significance, however, has yet to be determined. The 2021 updated diagnostic criteria for paraneoplastic neurologic symptoms help to establish the diagnosis of PCD, direct cancer screening, and to evaluate the presence of these newly identified antibodies. Recognition of the clinical syndrome and prompt identification of a specific antibody are essential for early detection of an underlying malignancy and initiation of an appropriate treatment, which represents the best opportunity to modulate the course of the disease. As clinical symptoms can precede tumor diagnosis by years, co-occurrence of specific symptoms and antibodies should prompt continuous surveillance of the patient. <b>Summary:</b> We provide an in-depth overview on PCD, summarize recent findings related to PCD, and highlight the transformed diagnostic approach.
format	article
author	Philipp Alexander Loehrer Lara Zieger Ole J. Simon
author_facet	Philipp Alexander Loehrer Lara Zieger Ole J. Simon
author_sort	Philipp Alexander Loehrer
title	Update on Paraneoplastic Cerebellar Degeneration
title_short	Update on Paraneoplastic Cerebellar Degeneration
title_full	Update on Paraneoplastic Cerebellar Degeneration
title_fullStr	Update on Paraneoplastic Cerebellar Degeneration
title_full_unstemmed	Update on Paraneoplastic Cerebellar Degeneration
title_sort	update on paraneoplastic cerebellar degeneration
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/da0a4808024c47eebf6ab585dbdd5942
work_keys_str_mv	AT philippalexanderloehrer updateonparaneoplasticcerebellardegeneration AT larazieger updateonparaneoplasticcerebellardegeneration AT olejsimon updateonparaneoplasticcerebellardegeneration
_version_	1718412866090958848

Update on Paraneoplastic Cerebellar Degeneration

Ejemplares similares